Gene · 977
Papers2,195
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,195
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CRISPRepi: a multi-omic atlas for CRISPR-based epigenome editing. | Nucleic Acids Res | 2025 | 39530233 | PubTator, text mining | PubMed |
| FAPM: functional annotation of proteins using multimodal models beyond structural modeling. | Bioinformatics | 2024 | 39540736 | PubTator, text mining | PubMed |
| Liquid Biopsy in Lung Cancer: Nano-Flow Cytometry Detection of Non-Small Cell Lung Cancer in Blood. | Lab Invest | 2024 | 39419350 | PubTator, text mining | PubMed |
| CD151 identifies an NK cell subset that is enriched in COVID-19 patients and correlates with disease severity. | J Infect | 2024 | 39374860 | PubTator, text mining | PubMed |
| Integrin α6-containing extracellular vesicles promote lymphatic remodelling for pre-metastatic niche formation in lymph nodes via interplay with CD151. | J Extracell Vesicles | 2024 | 39329462 | PubTator, text mining | PubMed |
| Combined knockdown of CD151 and MMP9 may inhibit the malignant biological behaviours of triple-negative breast cancer through the GSK-3β/β-catenin-related pathway. | Sci Rep | 2024 | 39294214 | PubTator, text mining | PubMed |
| Combination of ionizing radiation and 2-thio-6-azauridine induces cell death in radioresistant triple negative breast cancer cells by downregulating CD151 expression. | Cancer Chemother Pharmacol | 2024 | 39167147 | PubTator, text mining | PubMed |
| In silico study suggests potential drugs that target CD151 to treat breast cancer and glioblastoma. | J Comput Chem | 2024 | 39082832 | PubTator, text mining | PubMed |
| A novel basement membrane-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma. | Front Oncol | 2024 | 39070142 | PubTator, text mining | PubMed |
| Impact of CD151 overexpression on prognosis and therapy in non-small cell lung cancer patients lacking EGFR mutations. | Cell Prolif | 2024 | 38982031 | PubTator, text mining | PubMed |
| The proliferation/migration ability mediated by CD151/PI3K/AKT pathway determines the therapeutic effect of hUC-MSCs transplantation on rheumatoid arthritis. | Clin Exp Hypertens | 2024 | 38864268 | PubTator, text mining | PubMed |
| Antiviral activity and underlying mechanisms of baicalin against porcine reproductive and respiratory syndrome virus in vitro. | Microb Pathog | 2024 | 38851360 | PubTator, text mining | PubMed |
| CD151-enriched migrasomes mediate hepatocellular carcinoma invasion by conditioning cancer cells and promoting angiogenesis. | J Exp Clin Cancer Res | 2024 | 38840183 | PubTator, text mining | PubMed |
| INHIBITION OF INTEGRIN VLA-3 AND TETRASPANIN CD151 PROTECTS AGAINST NEUTROPHIL-MEDIATED ENDOTHELIAL DAMAGE. | Shock | 2024 | 38813923 | PubTator, text mining | PubMed |
| Redefining Debt-to-Health, a triple-win health financing instrument in global health. | Global Health | 2024 | 38711129 | PubTator, text mining | PubMed |
| Synthetic phage-based approach for sensitive and specific detection of Escherichia coli O157. | Commun Biol | 2024 | 38710842 | PubTator, text mining | PubMed |
| Involvement of the Cell Division Protein DamX in the Infection Process of Bacteriophage T4. | Viruses | 2024 | 38675830 | PubTator, text mining | PubMed |
| Label-Free Multiplex Profiling of Exosomal Proteins with a Deep Learning-Driven 3D Surround-Enhancing SERS Platform for Early Cancer Diagnosis. | Anal Chem | 2024 | 38624007 | PubTator, text mining | PubMed |
| Extracellular Vesicles as Next-Generation Biomarkers in Lung Cancer Patients: A Case Report on Adenocarcinoma and Squamous Cell Carcinoma. | Life (Basel) | 2024 | 38541732 | PubTator, text mining | PubMed |
| Utilizing Magnetic Levitation to Detect Lung Cancer-Associated Exosomes. | ACS Sens | 2024 | 38520356 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/977/papers?page=5